ReviewFrontiers in pharmacology2025
Unlocking the secrets of glucose metabolism reprogramming: the role in pulmonary diseases.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming is the process by which cells adapt to different patterns of energy metabolism in response to the demands of the microenvironment for energy and biological macromolecules. Glucose serves as the primary energy source for cellular survival, and its metabolic pathways are intricately associated with cellular functional states. Recent studies have demonstrated that alterations in glucose metabolism, along with non-metabolic functions of metabolic enzymes and metabolites, play crucial roles in the development and progression of lung diseases under inflammatory conditions. This review summarizes the regulatory mechanisms of glucose metabolism across various pulmonary disorders and discusses the non-metabolic functions of glycolytic enzymes and metabolites in relation to disease pathogenesis. We aim to shine new light on the diagnosis and treatment of lung disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.